In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers.
Penn in the news
Meeta Prasad Kerlin and Scott Halpern of the Perelman School of Medicine are quoted about the effect of nighttime attending physicians on patient outcomes.
Ethan Mollick of the Wharton School comments on Yahoo acquiring the micro-blogging site Tumblr.
Susan Domchek of the Perelman School of Medicine comments on testing for BRCA mutation carriers.
Gustavo Aguirre of the School of Veterinary Medicine is interviewed about offering free vision screenings for service dogs.
Lillian Aronson of the School of Veterinary Medicine comments on a cat receiving kidney transplant surgery.